Racotumomab
- Generic Name
- Racotumomab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 946832-34-4
- Unique Ingredient Identifier
- 52G405U1E5
- Background
Racotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
- Associated Conditions
- -
- Associated Therapies
- -
Racotumomab in Patients With High-risk Neuroblastoma
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 39
- Registration Number
- NCT02998983
- Locations
- 🇦🇷
Prof. Dr. J. P. Garrahan National Children's Hospital, Buenos Aires, Argentina
🇦🇷Hospital Universitario Austral, Pilar, Buenos Aires, Argentina
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 15
- Registration Number
- NCT01598454
- Locations
- 🇦🇷
Prof. Dr. J. P. Garrahan National Children's Hospital, Buenos Aires, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath